RKD Vasculitis COVID-19 Module

Created by: Jennifer Scott (Wellcome-HRB ICAT fellow) and Matthew Rutherford (Clinical academic renal fellow, UK)

The following was constructed as a means to capture data for immunosuppressed patients who contract COVID-19 (C-19). The aim was to ensure the module was granular, while still allowing for a busy clinician to complete it in a timely fashion. There is a large emphasis on interoperability (e.g. the use of standardised ontologies) and including fields to facilitate collaboration with other research groups. This C-19 module/instrument was developed using the following:

- SECURE-IBD (IBD C-19 registry) data dictionary
- COVID-19 Global Rheumatological Alliance data dictionary
- Data dictionary from https://rheum-covid.org/
- Health Protection Surveillance Centre (HPSC Ireland) Critical Care surveillance forms
- WHO COVID-19 surveillance CRF
- Comments from the UKIVAS group: Mark Little, Neil Basu, Rona Smith, Alan Salama, David Jayne, Silke Brix
- COVID-19 existing literature as of 23rd March 2020.

We have maintained existing relevant fields in existing instruments (visuals included below, and shaded in orange) and added an additional COVID-19 specific instrument, which was modelled on our current 'encounter' instrument (used for clinic visits) – the information will populate a simultaneous encounter (as a pop-up within the COVID-19 instrument) and other relevant fields (via piping).

Dissemination:
REDCAP has the capability of quick exports and rough raw statistics. The plan is to distribute a **weekly email** to give researchers and clinicians real-time information. R markdown is a potential option to standardise reports and graphics.

Instrument (new): COVID-19

Field Label	Field Type	Choices
Reporter information		
Name of physician providing care for vasculitis patient	Text	
Name of centre providing care	Dropdown	Current hospital dropdown from 'Patient' – 'Hospital Unit', including 'other' as last option
Date this form completed	Calendar (Default = Today)	
Please select all databases this form has been shared with	Checkbox	Irish RKD / UKIVAS / EULAR / Global COVID

For 'Patient information', only non-orange fields appear in the COVID-19 instrument (as below):

Patient information (Part 1)

Country of residence	Ⓗ 💬	Ireland ⬍
County of residence	Ⓗ 💬	⬍
Education	Ⓗ 💬	⬍
E-cigarette or Vape use	Ⓗ 💬	⬍

Patient information		
Gender	Dropdown	Male / Female / Other *RKD: pipe in from 'baseline characteristics – common'*
Race (select all that apply)	Checkbox	*RKD: piping from 'ethnicity' in 'baseline characteristics – common'*
Country of residence	Dropdown	*RKD: Default = Ireland* **NEW RKD FIELD - below 'country of birth' in 'baseline characteristics – common'**
County of residence	Dropdown	*RKD: 32 counties listed in alphabetical order & 'other' with free text* **NEW RKD FIELD - below 'country of residence' in 'baseline characteristics – common'**
Education	Dropdown	Primary School / High school / University / Unknown or Prefer not to answer **NEW RKD FIELD- above 'employment status at diagnosis' in 'baseline characteristics – common'**
Smoking history	Dropdown	Current Smoker/ Former Smoker/ Never Smoker/ Unknown smoking status *RKD: pipe from smoking history in 'baseline characteristics – common'*
E-cigarette or Vape use	Dropdown	Yes / No / Unknown

		NEW RKD FIELD - add below the 'smoking history' field in 'baseline characteristics – common'
Comorbidities (check all that apply)	Checkbox	Asthma - SNOMEDCT/195967001 // Atrial fibrillation - SNOMEDCT/49436004 // Cerebrovascular accident (stroke) - SNOMEDCT/230690007 // COPD (not including late onset asthma) - SNOMEDCT/13645005 // Coronary heart disease (Ischaemic heart disease) - SNOMEDCT/414545008 // Diabetes mellitus - SNOMEDCT/73211009 // Hyperlipidaemia - SNOMEDCT/55822004 // Hypertension requiring treatment - SNOMEDCT/38341003 // Hypothyroidism - SNOMEDCT/40930008 // Renal disease (kidney disease) - SNOMEDCT/90708001 // Thromboembolic disease - SNOMEDCT/371039008 // Other (SNOMEDCT ontology) // None *RKD: pipe selected comorbidities from 'pre-existing co-morbidities' instrument (see image below)*

For **'Patient information (part 2)'**, all fields are obtained from existing fields, as explained for each variable. **It is important these fields are completed in the relevant sections** to ensure an enriched dataset:

Patient information (part 2)		
Vasculitis diagnosis	Dropdown	See standard UKIVAS options below *RKD: pipe in from 'Diagnosis – Vasculitis': either 'Small vessel*

		vasculitis (ANCA associated)' OR 'Small vessel vasculitis (Immune Complex)' OR 'Medium vessel vasculitis' OR 'Large vessel vasculitis' OR 'Variable vessel vasculitis' OR 'Single organ vasculitis'
ANCA serology (at time of diagnosis)	Dropdown	PR3 / MPO / PR3 and MPO / ELISA negative / No ELISA performed / Other (free text) *RKD: pipe in from 'General characteristics – vasculitis' -> 'At any point ANCA Specificity'*
Date of formal vasculitis diagnosis	Calendar	*RKD: pipe in from 'Diagnosis – Vasculitis': 'Date of diagnosis'*
Biopsy performed	Dropdown	Yes / No / Unknown *RKD: pipe in from 'Diagnosis – Vasculitis' – same field*
Histologically confirmed diagnosis	Dropdown	Yes / No / Unknown *RKD: pipe in from 'Diagnosis – Vasculitis' – same field*
Vasculitis diagnosis confidence *Attach reference to diagnosis confidence table*	Dropdown	Possible / Probable / Definite *RKD: pipe in from 'Diagnosis – Vasculitis' – same field*

For **'Vasculitis/Disease status at time of C-19 diagnosis'**:

- Complete ESKD and VDI Score, as detailed below:

End-stage Kidney Disease (ESKD)	Radio button	Yes / No *RKD: piped to 'Renal Replacement Therapy' – 'End-stage kidney disease'*
If ESKD = Yes Date of End-stage Kidney Disease (*Date of*	Calender	*RKD: piped to 'Renal Replacement Therapy' – 'Date of End-stage kidney disease'*

commencement on dialysis or transplant, whichever first)		
If ESKD = Yes Type of Renal Replacement Therapy (RRT)	Dropdown	Functioning renal transplant / Haemodialysis / Peritoneal Dialysis / Sustained CKD V
VDI Score	RKD: Integer	

- Then **click 'New Encounter Instance'**, to reveal a pop-up window containing the usual 'encounter' instrument (see below). Complete this in full:
    - Select 'yes' for 'COVID-19 related entry'
    - Click 'Save & exit form' at the bottom of the pop-up after completing all fields
    - Then click 'x' in top right corner to close the pop-up

    - This section includes the following variables:

Vasculitis/Disease status at time of C-19 diagnosis		
Employment status	Dropdown	Employed full-time / Employed part-time / Retired / Disability benefit / Student / Not working / Unknown
Disease activity at time of C-19 symptom onset or diagnosis if asymptomatic (physician global)	Dropdown	*Active / Low disease activity / Remission*
Urinalysis Done	Radio button	Yes / No
If Urinalysis = Yes: Urinalysis Protein	Radio button	Negative / +1 / +2 / > = +3
If Urinalysis = Yes:	Radio button	Negative / +1 / +2 / > = +3

Urinalysis Blood		
Last eGFR (CKD-EPI) prior to C-19 diagnosis **This field is obtained from the preceeding encounter for the bespoke export. No additional data entry is required for this field.**	Integer	*Field Note: Please enter NA if the patient was dialysis dependent at that time*
Dialysis dependent	Radio button	Yes / No Field note: 'If patient has started/stopped dialysis since the last encounter, please input relevant dates into 'Renal Replacement Therapy' instrument.
If Dialysis dependent = yes Date of dialysis start +/- stop	Calender	
Weight (kg)	Number (allow 1 decimal point)	
Height (m)	Please complete in *'baseline characteristics – common'*	
BMI	Calculated field = weight (kg from above) / height^2 (m, from above)	
Clinical samples obtained	Tick boxes	1, Plasma exchange fluid 2, Serum 3, Urine 4, DNA extracted from saliva 5, Saliva for DNA 6, PAX gene tube for RNA 7, EDTA for PBMC 8, EDTA for DNA 9, Tissue 10, EDTA for plasma 11, none
BVAS Scoring	FULL BVAS (see SOP: clinical data entry for full explanation): radio button & tick boxes for each variable	
BVAS Score	Calculated field	
Do you think vasculitis is relapsing in this encounter? *This is the physician's assessment at the time of clinical review.*	Dropdown	High probability / Possibly / No / Unknown

Adjudicated probability of relapse? *This field is completed retrospectively by senior clinician, taking all variables into account (e.g. clinical signs/symptoms, laboratory values, biopsy, etc.)*	Dropdown	Definite / High Probability / Possibly / No *Information link (hover over 'i in blue circle') to see definitions of Definite / High Probability, etc.*

Medication *includes **any medication the patient is on <u>within 2 weeks of COVID-19 diagnosis</u>** AND *all questions relate to **drugs/doses at time of C-19 symptom onset (or diagnosis if asymptomatic)** ==*Please ensure* **'Treatment - continuing medication'** *AND* **'Treatment – intermittent pulse administration'** *is up to date in terms of dose and start/stop dates for all immunosuppressive medications.*==		
Immunosuppressive status	Dropdown	Currently on immunosuppression / Discontinuation of immunosuppression within 6 months prior to this encounter / Discontinuation of immunosuppression > 6 months prior to this encounter / Treatment Naïve
If Immunosuppressive status != (not equals) 'Treatment Naïve' Corticosteroids	Radio button	Yes / No
If Corticosteroids = Yes Current corticosteroid dose	Radio button (RKD)	< 5 mg/day / 5-10 mg/day / 11-20 mg/day / > 20 mg/day
Corticosteroids in response to this clinical encounter/episode	Dropdown	Increased / No change / Reduced / Stopped / Unknown
If Immunosuppressive status != (not equals) 'Treatment Naïve' Immunosuppressive medication **For implementation:**	Dropdown	Select medication from dropdown list. If it is not listed, select 'other' and enter the medication in the new field that appears, using an ATC backed ontology (i.e. when you begin to type the ontology will suggest medications to

Patients may be on >1 Immunosuppressive agent. If so, select the second agent from the field *'Additional Immunosuppressive medication'*. Consequently, complete whether this additional agent was increased / no change / reduce, etc. **If the patient is not on any additional agents, leave this blank.**		select). **The following are a list of medications that we are particularly interesting in capturing (with the associated ACT ontology):** Abatacept – UATC/L04AA24 Alfa1 antitrypsin – UATC/B02AB02 Anakinra – UATC/L04AC03 Apremilast – UATC/L04AA32 Azathioprine - UATC/L04AX01 Belimumab – UATC/L04AA26 Bevacizumab – UATC/L01XC07 Ciclesonide – UATC/R03BA08 Ciclosporin – UATC/L04AD01 Chloroquine – UATC/P01BA01 Cyclophosphamide (Daily Oral) – UATC/LC01AA01 Cyclophosphamide (Intravenous pulse) – UATC/LC01AA01 Hydroxychloroquine – UATC/P01BA02 IVIG: Immunoglobulins – UATC/J06BA02 Leflunomide - UATC/L04AA13 Mepolizumab - UATC/R03DX09 Methotrexate - UATC/L01BA01 Mycophenolate mofetil - UATC/L04AA06 Plasma (from recovered patients) – UATC/B05AX03 // Rituximab - UATC/L01XCO2 Secukinumab – UATC/L04AC10 Sulfasalazine – UATC/A07EC01 Tacrolimus (including Advagraf, Prograf, etc.) - UATC/L04AD02 Thalidomide – UATC/L04AX02 Tocilizumab – UATC/L04AC07 Tofacitinib – UATC/L04AA29 Tumor necrosis factor alpha (TNF-) inhibitors – UATC/L04AB Ustekinumab - UATC/L04AC05 Other – ATC backed ontology // None // Unknown
Immunosuppressive medication in response to this clinical encounter/episode	Dropdown	Increased / No change / Reduced / Stopped / Unknown
If Immunosuppressive medication in response to this clinical encounter/episode = Increased: Response to increased immunosupupresion	Dropdown	Clear response (i.e. improved clinically) / No response / Unknown response

- The remaining encounter instrument includes fields surrounding prophylactic medication and laboratory results. Please see the SOP: clinical data entry for further instructions.
- For Investigations summary: XXX
- Other medication variables to complete on the main C19 instrument include:

Angiotensin-converting-enzyme inhibitor at C19 diagnosis (ACE-i)	Radio button	Yes / No / Unknown
Angiotensin II receptor blocker at C19 diagnosis (ARB)	Radio button	Yes / No / Unknown
Non-steroidal anti-inflammatory drug at C19 diagnosis (NSAID)	Radio button	Yes / No / Unknown

COVID-19 Questions		
Date of C-19 symptom onset (if known)	Calendar	
Date of C-19 diagnosis	Calendar	
Interval (days) between symptom onset and diagnosis (if known)	Calculated field using 'date of C19 symptom onset' and 'date of C19 diagnosis'	
Age at C-19 diagnosis (years)	Calculated field using DOB ('Baseline characteristics – common')	
Location at which C-19 diagnosis was made	Dropdown	1, Home or standalone testing | 2, Nursing home or assisted living facility | 3, Outpatient facility | 4, Emergency Room | 5, Inpatient/Hospital | 6, Other (freetext) | 7, Unknown
Method of C-19 testing (select the most objective option)	Dropdown	1, symptoms (presumptive) | 2, PCR | 3, antibody | 4, metagenomic testing | 5, CT scan | 6, other (free text) |7, Laboratory assay, type unknown
If Method = PCR: Level of Sars-CoV-2 (COVID-19) PCR	Integer	
Sars-CoV-2 (COVID-19) IgM	Integer	
Sars-CoV-2 (COVID-19) IgG	Integer	
Admission to hospital required *If Yes:* Date of admission	Radio button Calendar	Yes /No/ Unknown
Admission to Intensive Care Unit *If Yes:* Date of admission	Radio button Calendar	Yes /No/ Unknown
Interval (months) from AAV diagnosis to C-19 diagnosis	Calculated field using Date of	

		diagnosis ('Diagnosis – vasculitis')	
Have patient's symptoms resolved at time of this report?	Dropdown	1, yes | 2, no | 3, unknown | 4, Asymptomatic patient (just tested positive)
If Have patient's symptoms resolved at time of this report? = yes Date of symptom resolution (if known)	Calendar	*Field note: first date patient is asymptomatic, signifying recovery*
Interval (days) between symptom onset (if known) and symptom resolution OR current date (if symptoms persist)	Calculated field using 'date of symptom onset' and 'date of symptom resolution' (if not known use 'today's date')	
Date of hospital discharge (if known)	Calendar	
Length of stay (days)	Calculated field using 'date of admission' and 'date of hospital discharge'	
Infection Acquisition	Dropdown	High-risk travel to endemic area / Contact of known or suspected person / Attendance to a healthcare facility/ward where C-19 infections are managed / None of the above (community acquired) / Unknown
Clinical features at outset (check all that apply)	Checkbox	Fever – MEDDRA/10016558 / Malaise – MEDDRA/10025482/ Headache – MEDDRA/10019211/ Irritability or confusion – MEDDRA/10010300 / Arthralgia – MEDDRA/10003239 / Myalgia – MEDDRA/10028411 / Conjunctivitis – MEDDRA/10010741 / Rhinorrhea – MEDDRA/10039101 / Anosmia – MEDDRA/10002653 (Loss of smell) / Ageusia – MEDDRA/10001480 (Loss of taste) Sore Throat – MEDDRA/10041367 / Cough – MEDDRA/10011224 / Sputum production – MEDDRA/10041805 / Shortness of Breath – MEDDRA/10040604 / Chest pain – MEDDRA/10008479 / RR >24 breaths/min – MEDDRA/10038711/

		Abdominal pain – MEDDRA/10000081/ Nausea – MEDDRA/10028813 / Vomiting – MEDDRA/10047700 / Diarrhea – MEDDRA/10012735 / **Other (MEDDRA Ontology)** / None (asymptomatic) / Unknown
Body temperature (**highest recorded**, °C)	Number (allow 1 decimal) Validation: only allow range 13 - 46°C	
CRP (mg/L) Field note: Please enter the **highest/peak** recorded lab value for each field	Number (allow 1 decimal) RKD: for all lab values pipe to corresponding field in 'encounters'	Some lab values are entered in the encounter pop-up (as described in the sop: clinical data entry) and the remaining C19 specific lab values are completed in the COVID-19 instrument (these are highlighted in yellow).
Creatinine (mmol/L)	Integer	
AST (U/L)	Integer	
ALT (U/L)	Integer	
Haemoglobin (g/dL)		
Total White Cell Count x 10^9/L	Number (allow 1 decimal)	
Neutrophil count x 10^9/L	Number (allow 1 decimal)	
Lymphocyte count x 10^9/L	Number (allow 1 decimal)	
Neutrophil / Lymphocyte ratio	Calculated field	
Urine Protein Creatinine ratio (uPCR, mg/mmol)		
ANCA IF	Dropdown	Atypical / C / P / Negative / Not tested / Pending
Anti-PR3 level	Integer	
Anti-MPO level	Integer	
Platelet count x 10^9/L	Integer	
Creatinine kinase (U/L)	Integer	
D-dimer (mg/L)	Integer	
Ferritin	Integer	
Lactate (mg/dL)		
Prothrombin time (s)	Number (allow 1 decimal)	
Lactate dehydrogenase (U/L)	Integer	
Troponin	Integer	
Next to 'Troponin': Units	Dropdown	

Findings on chest imaging	Dropdown	Inflammation Ischaemia Infarction Haemorrhage Bony destruction Metastasis Mass/tumour Abscess Polyp Ulceration Cirrhosis Fibrosis Stenosis Calcification Effusion Embolism Nodules Consolidation Organomegaly Single granuloma Multiple granulomas None
Were antibiotics administered?	Radio button	Yes / No / Unknown
Was treatment administered for C-19 infection (other than best supportive care)?	Checkbox	No treatment except supportive care Kaletra ((Lopinavir/ritonavir) – UATC/J05AR10 Remdesivir – **No ontology code yet as novel** Chloroquine – UATC/P01BA01 Hydroxychloroquine – UATC/P01BA02 **Neuraminidase inhibitors, direct acting antivirals (e.g. Oseltamivir) – UATC/J05AH** **Azithromycin – UATC/S01AA26** Tocilizumab – UATC/L04AC07 Bevacizumab – UATC/L01XC07 Tofacitinib – UATC/L04AA29 Alfa1 antitrypsin – UATC/B02AB02 Ciclesonide – UATC/R03BA08 Plasma (from recovered patients) – UATC/B05AX03 Other – ATC backed ontology
Complications / Disease Course (check all that apply)	Checkbox	Acute Respiratory Distress Syndrome – MEDDRA/10001052 / Acute respiratory failure (Type 1/2) – MEDDRA/10001053 / Pneumothorax – MEDDRA/10035759 / Acute liver injury – MEDDRA/10067970 / Acute heart failure – MEDDRA/10000803 / Myocarditis – MEDDRA/10028606 / Cardiac arrhythmia – MEDDRA/10003119 / Cardiac ischaemia – MEDDRA/10007584 / Acute Kidney Injury (AKI) – MEDDRA/10069339 / Sepsis – MEDDRA/10040047 / Vasopressor dependence at any time – MEDDRA/10064148 / Disseminated Intravascular Coagulation – MEDDRA/10013442 / Severe anaemia – MEDDRA/10002082 / Gastrointestinal haemorrhage – MEDDRA/10017956 /

		Encephalitis – MEDDRA/10014581 / Pregnancy-related complications – MEDDRA/10036569 / Hyperglycaemia – MEDDRA/10020637 / Hypoglycaemia – MEDDRA/10020996 / Rhabdomyolysis – MEDDRA/10039020 / Metabolic acidosis – MEDDRA/10027417 / Secondary infection – MEDDRA/10062158 / Macrophage activation syndrome – MEDDRA/10053867 / **Other (MEDDRA ontology) /** **None**
If AKI = selected, then please complete the following fields in the encounter pop-up. (highlighted) **Dialysis dependent, Date of dialysis start +/- Date of dialysis stop** (highlighted)		
Concomitant respiratory pathogens detected (select all that apply):	Checkbox	Influenza A Influenza B NON-COVID-19 Coronavirus Respiratory syncytial virus (RSV) Adenovirus
If Secondary Infection = selected Secondary infection is selected, please indicate the type of Infection (in addition concomitant respiratory viral pathogens)	Dropdown	Bacteremia (5758002) Pneumonia (233604007) Pyelonephritis (4581600) Gastroenteritis (25374005) Encephalitis (45170000) Cellulitis (128045006) Osteomyelitis (60168000) ✓ Other Other using SNOMEDCT ontology
If Secondary Infection = selected With regards to the secondary infection, please select the microorganism (if known)	SNOMEDCT ontology	Begin typing the name of the microorganism into the field and the ontology will begin to suggest matches.
C-19 Outcome (Select the highest level of support the patient received)	Dropdown	1. Not hospitalized, no limitations on activities 2. Not hospitalized, limitation on activities 3. Hospitalized, not requiring supplemental oxygen 4. Hospitalized, requiring supplemental oxygen

		5. Hospitalized, on non-invasive ventilation or high flow oxygen devices 6. Hospitalized, on invasive mechanical ventilation or ECMO 7. Death 8. Unknown
If C-19 outcome = 7. Death Date of death	Calendar RKD: pipe to 'date of event' in 'baseline characteristics – common'	
If C-19 outcome = 7. Death Cause of death	SNOMEDCT ontology RKD: pipe to 'cause of death' in 'baseline characteristics – common'	
May we contact you to get more information about the outcomes of this case?	Radio button	Yes / No
Would you like to share any lessons or other aspects from this case? Please include as much information as desired, this will greatly help patients and colleagues.	Text	

Current relevant instruments in RKD Registry
Relevant fields identified with red box. For more details please refer to SOP: Clinical Data Entry

Smoking History

Smoking	Ⓗ 💬	Previous ⬍
Age of starting	Ⓗ 💬	21
Date of stopping	Ⓗ 💬	18-03-2020 📅 Today D-M-Y
Average no. of cigarettes per day	Ⓗ 💬	20

Patient Status

Status	Ⓗ 💬	Dead ⬍
Death	Ⓗ 💬	◯ Yes ⦿ No
Date of event	Ⓗ 💬	___ 📅 Today D-M-Y
Cause of death	Ⓗ 💬	⬍
Cause of death - Known	Ⓗ	___
Cause of death - known, snomedCT	Ⓗ 💬	Coronavirus infection 186747009 snomedCT

Form Status

Complete?	Ⓗ 💬	Complete ⬍

📄 **Renal Replacement Therapy**

🖊 Editing existing RKD ID **10** (Patient Id **10**) 10	
RKD ID	10
Required renal replacement therapy during first presentation Ⓗ 💬	⦿ Yes ◯ No reset
Renal recovery (independence from dialysis, regardless of dialysis duration) Ⓗ 💬	◯ Yes ⦿ No reset
End-stage kidney disease Ⓗ 💬	⦿ Yes ◯ No reset Dialysis for >90 days, sustained CKD V, commencement of dialysis and death within 90 days, and/or transplantation
Date of end-stage kidney disease (date of commencement on dialysis or transplant, whichever first) Ⓗ 💬	18-03-2020 📅 Today D-M-Y If patient develops ESKD after initially recovering from dialysis-dependent kidney failure, enter the date that ESKD develops

Form Status

Complete?	Ⓗ 💬	Incomplete ⬍

Save & Exit Form   Save & Stay ▾

-- Cancel --

RKD ID	10

Please enter only one comorbid event per instance.

Comorbid events (present before vasculitis diagnosis)	☐ Asthma - SNOMEDCT/195967001
	☐ Atrial fibrillation - SNOMEDCT/49436004
	☐ Cerebrovascular accident (stroke) -
	    SNOMEDCT/230690007
	☐ COPD (not including late onset asthma) -
	    SNOMEDCT/13645005
	☐ Coronary heart disease (Ischaemic heart disease) -
	    SNOMEDCT/414545008
	☐ Diabetes mellitus - SNOMEDCT/73211009
	☐ Hyperlipidaemia - SNOMEDCT/55822004
	☐ Hypertension requiring treatment -
	    SNOMEDCT/38341003
	☐ Hypothyroidism - SNOMEDCT/40930008
	☐ Malignancy (neoplasm) - SNOMEDCT/108369006
	☐ Renal disease (kidney disease) -
	    SNOMEDCT/90708001
	☐ Thromboembolic disease - SNOMEDCT/371039008
	☐ Other
	☑ None

Comorbid events (present before vasculitis diagnosis)	⬍
Comorbid events detail	

Form Status	
Complete?	Complete ⬍

📄 Diagnosis - Vasculitis

✏️ Editing existing RKD ID **10** (Patient Id **10**)   10

RKD ID	10
Date of diagnosis	⊞ [Today] D-M-Y JRC
Age at diagnosis	[ ] View equation JRC
Date of onset of symptoms - known/unknown	[Unknown ▾]
Date of onset of symptons	⊞ [Today] D-M-Y JRC
Age at onset	[ ] View equation JRC
Small vessel vasculitis (ANCA associated)	[Granulomatosis with polyangiitis (Wegener) - ▾]
Please select up to a MAXIMUM of 3 diagnoses	
Small vessel vasculitis (Immune complex)	[▾]
Medium vessel vasculitis	[▾]
Large vessel vasculitis	[▾]
Variable vessel vasculitis	[▾]
Single organ vasculitis	[▾]
Secondary vasculitis	○ Yes ○ No reset
Other	● Yes ○ No reset
Other details	[ ]
Unclassified	○ Yes ○ No reset
Biopsy performed	[Yes ▾]
Histologically confirmed diagnosis	[Yes ▾]
Please open supporting PDF for reference Attachment: 📄 Diagnosis confidence table.pdf (0.1? MB)	
Diagnosis confidence (initial assessment)	[Definite ▾]
Form Status	
Complete?	[Complete ▾]

Treatment – continuing medications (PO)

	Drug	Dose	Unit of Dose	Start Date	Stop Date
1	Prednisolone - UATC/H02AB06	5	mg	2013-02-03	2014-10-16
2	Prednisolone - UATC/H02AB06	10	mg	2014-10-16	2018-01-05
3	Prednisolone - UATC/H02AB06	5	mg	2016-07-22	2017-12-10
4	Other	40	g	2016-11-08	

Current instance: ⊙ 5 ▽

✎ Editing existing RKD ID **10** (Instance #5) (Patient Id **10**) 10

RKD ID		10
Drug	Ⓗ 💬	[ ]
Drug, DRON	Ⓗ 💬	[ ]
Drug	Ⓗ 💬	Other ▲▼
Drug, ATC	Ⓗ 💬	ramipril C09AA05
Dose	Ⓗ 💬	5
Unit of Doses	Ⓗ 💬	mg ▲▼
Frequency	Ⓗ 💬	Daily ▲▼
Start Date	Ⓗ 💬	18-03-2020 📅 Today D-M-Y
On going	Ⓗ 💬	⦿ Yes ◯ No reset
Stop Date	Ⓗ 💬	[ ] 📅 Today D-M-Y
Form Status		
Complete?	Ⓗ 💬	Incomplete ▲▼

Treatment – intermittent pulse administration (IV)

✎ Editing existing RKD ID **10** (Patient Id **10**) 10

RKD ID		
IV therapy		✓ Cyclophosphamide Injectable Solution - UATC/ L01AA01
		Rituximab - UATC/L01XC02 -- Mabthera
		Rituximab - UATC/L01XC02 -- Truxima
Date of IV therapy		Methylprednisolone - UATC/D07AA01
		Ivlg - UATC/J06BA02 (immunoglobulins, normal human, for intravenous administration)
Dose of IV therapy		Mepolizumab - UATC/R03DX09
		Other
Unit of dose	Ⓗ 💬	mg ▲▼
Form Status		
Complete?	Ⓗ 💬	Complete ▲▼

References

Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med Published Online First: 3 March 2020. doi:10.1007/s00134-020-05991-x

Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA Published Online First: 7 February 2020. doi:10.1001/jama.2020.1585

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.

Xu X-W, Wu X-X, Jiang X-G, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 2020;368:m606.

Guan W-J, Ni Z-Y, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med Published Online First: 28 February 2020. doi:10.1056/NEJMoa2002032

Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019;200:e45–67.

HPSC Surveillance:
https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/surveillance/ADULT%20influenza%20&%20COVID%2019%20ICU%20Admission&%20Discharge%20form_20200303_%20v032.pdf